Welcome to our dedicated page for Inflarx SEC filings (Ticker: IFRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to InflaRx N.V. (Nasdaq: IFRX) SEC filings, where the company discloses financial results, clinical updates and key corporate information as a foreign private issuer. InflaRx files annual reports on Form 20-F and current reports on Form 6-K that include unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and detailed descriptions of clinical and regulatory developments.
Through these filings, readers can review how InflaRx reports progress with its complement-focused pipeline, including the oral C5a receptor inhibitor izicopan (INF904) and the anti-C5a monoclonal antibody vilobelimab. Selected 6-K reports incorporate press releases and presentations on Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, analyses of Phase 3 data in pyoderma gangrenosum, and updates on BARDA-supported studies in acute respiratory distress syndrome.
InflaRx’s SEC filings also document matters such as changes in independent auditors, notices from Nasdaq regarding minimum bid price requirements and subsequent compliance, and information about collaboration arrangements, including royalty-bearing rights related to the anti-C5a antibody BDB-001 in China. Financial sections outline revenues, research and development expenses, sales and marketing costs, general and administrative expenses, cash balances and financing activities.
On Stock Titan, InflaRx filings are updated as new documents are released on EDGAR. AI-powered tools can help summarize lengthy 20-F and 6-K reports, highlight key points about IFRX’s clinical programs, and surface information on risk factors, liquidity and capital resources. Users interested in insider or major shareholder activity can complement these filings with ownership and transaction data where available, while relying on the filings themselves for the company’s official narrative on its complement-system therapeutic strategy and financial position.
InflaRx N.V. has called its 2026 annual general meeting for April 23, 2026 in Amsterdam, setting a March 26, 2026 record date. Shareholders will vote on adopting the 2025 annual accounts, appointing KPMG as 2026 auditor, granting director discharge, and re-appointing four directors, including CEO and co-founder Prof. Niels Riedemann. Proposals include extending five-year authorizations for the board to issue shares and to limit or exclude pre-emption rights, renewing a share repurchase authorization for up to 10% of issued capital at up to 110% of the recent Nasdaq average price, and significantly increasing authorized share capital. The board also seeks approval for a new LTIP 2026 from January 1, 2027, raising the annual equity pool to 6.5% of outstanding shares from 4% under the prior plan.
InflaRx N.V. files its annual report on Form 20-F, highlighting ongoing losses and reliance on a small pipeline. The company reports net losses of €45.6 million, €46.1 million and €42.7 million for 2025, 2024 and 2023, with an accumulated deficit of €377.8 million as of December 31, 2025.
Operating cash outflows were €35.3 million in 2025 and €48.6 million in 2024, mainly for research and development. InflaRx depends on two key product candidates, izicopan and vilobelimab (GOHIBIC), and notes limited commercialization experience, including stopping its own GOHIBIC commercialization in the United States in 2025 due to lack of commercial success.
The company received government support, including a €33.3 million German grant over 2021–2023 and research allowances of €2.6 million in 2025 and €5.1 million in 2024, all subject to potential audit and clawback. InflaRx states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months but emphasizes the need for substantial additional funding to advance clinical programs.
InflaRx reported a 2025 net loss of €45.6 million (€0.68 per share), slightly improved from a €46.1 million loss in 2024 (€0.78 per share). Revenue remained minimal, while cost of sales rose due to a €4.0 million GOHIBIC inventory write-down tied to scaling back U.S. commercialization.
The company is refocusing on its oral C5aR inhibitor izicopan after positive Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, where it sees market opportunities each potentially exceeding $1 billion. R&D expenses fell to €25.7 million from €35.4 million as trials and manufacturing spending declined.
Marketing and sales costs dropped to €4.5 million, while general and administrative expenses edged up to €13.5 million. Total funds available were €46.2 million as of December 31, 2025, and management projects a cash runway to mid-2027 after raising €33.3 million net from share and pre-funded warrant issuances.
InflaRx N.V. director Mark Kubler filed an initial ownership report showing direct holdings of 960,015 Ordinary Shares of IFRX. He also reports several stock option awards over Ordinary Shares, including options over 7,308 shares at an exercise price of 0.0131 expiring on December 31, 2050. Most options described are fully vested and exercisable, while a grant made on January 6, 2026 for 30,000 underlying shares will vest in four equal installments of 7,500 shares on each quarterly anniversary of that grant date, subject to continued service.
InflaRx N.V. director Anthony S. Gibney filed an initial ownership report showing his equity stake. He holds 10,000 Ordinary Shares directly, plus several stock options over Ordinary Shares with exercise prices between $1.17 and $2.41 per share that expire from 2028 through 2036. Many of these options, granted between 2018 and 2025, are fully vested and exercisable, while a 30,000-share option granted on January 6, 2026 will vest in four equal quarterly installments, subject to continued service.
InflaRx N.V. director Richard Brudnick has filed an initial ownership report showing existing equity holdings. He directly holds 50,000 Ordinary Shares and multiple stock options over additional Ordinary Shares with exercise prices between $1.17 and $2.41 per share, expiring from 2029 through 2036. Most option grants are already fully vested and exercisable, while a January 2026 grant for 30,000 shares will vest in four equal quarterly installments of 7,500 shares, subject to continued service.
InflaRx N.V. director Hege Hellstrom has filed an initial ownership report showing existing stock option holdings in the company. The filing lists four stock option awards over ordinary shares with exercise prices of $4.19, $1.79, $2.41 and $1.17 per share and expirations from May 2033 through January 2036.
Options granted on May 31, 2023, January 5, 2024 and January 3, 2025 covering 22,500, 30,000 and 30,000 underlying ordinary shares are fully vested and exercisable. A further option granted on January 6, 2026 for 30,000 shares will vest in four equal quarterly installments of 7,500 shares, subject to continued service.
InflaRx N.V. director and Chief Scientific Officer Guo Renfeng filed an initial Form 3 showing his ownership in the company. He directly holds 1,762,144 Ordinary Shares and a series of stock options over additional Ordinary Shares with exercise prices ranging from 1.1700 to 2.4400, expiring between 2027 and 2036. Footnotes state that multiple option grants from 2016 through 2025 are already fully vested and exercisable, while a January 6, 2026 grant vests in four equal quarterly installments and a separate performance option depends on a financing event and the average Ordinary Share price in quarter four of 2026 exceeding $1.50.
InflaRx N.V. officer Derval O’Carroll filed an initial ownership report showing multiple stock option awards over Ordinary Shares. The holdings include options granted between November 2022 and January 2025 that are already fully vested and exercisable, plus a January 2026 grant that vests quarterly, subject to continued service.
The filing also lists a performance stock option granted on January 6, 2026, which can vest in two 50% tranches if a specified financing event occurs before the fourth quarter of 2026 and if the average Ordinary Share price in quarter four 2026 exceeds $1.50.
InflaRx N.V. director Nicolas Fulpius has filed an initial ownership report showing direct holdings of ordinary shares and stock options. He directly owns 490,052 ordinary shares. He also holds several stock option awards over ordinary shares with exercise prices between 1.17 and 2.41 per share and expiration dates running from late 2027 through early 2036. Footnotes state that most earlier option grants are already fully vested and exercisable, while an option granted on January 6, 2026 will vest in four equal quarterly installments of 11,250 shares, subject to continued service.